文献速递帕金森病与运动障碍

嗅神经元中的前动力蛋白-2作为帕金森病的潜在靶点

Olfactory Neuron Prokineticin-2 as a Potential Target in Parkinson's Disease.
PubMed 文献 · Ann Neurol · 2022-10-26

研究通过嗅黏膜刷取采集38例帕金森病患者(其中26例为新诊断未治疗)和31名性别年龄匹配健康对照的嗅神经元,检测前动力蛋白-2通路基因表达及α-突触核蛋白。发现患者前动力蛋白-2表达显著升高,新诊断患者更高且与MDS-UPDRS第三部分运动评分直接相关,寡聚体α-突触核蛋白升高且与前动力蛋白-2蛋白水平直接相关,总α-突触核蛋白无差异。

要点

  • 帕金森病患者嗅神经元前动力蛋白-2表达显著升高,新诊断患者更高。
  • 前动力蛋白-2水平与MDS-UPDRS第三部分运动评分直接相关。
  • 寡聚体α-突触核蛋白在患者中升高且与前动力蛋白-2蛋白水平直接相关。

核心结论

  • 前动力蛋白-2通路在帕金森病患者中被激活,早期阶段表达更高,与运动严重程度成比例,并与寡聚体α-突触核蛋白积累相关,支持其作为候选靶点。

研究设计与样本

  • 研究纳入38例帕金森病患者(其中26例为新诊断未治疗)和31名性别年龄匹配的健康对照,通过非侵入性黏膜刷取采集嗅神经元,进行标准临床评估。

主要发现

  • 帕金森病患者前动力蛋白-2表达显著增高,新诊断患者前动力蛋白-2水平更高,且与MDS-UPDRS第三部分运动评分直接相关。
  • 帕金森病患者寡聚体α-突触核蛋白更高,且与前动力蛋白-2蛋白水平直接相关;总α-突触核蛋白在患者与对照间无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to outline the dynamics of prokineticin-2 pathway in relation to clinical-pathological features of Parkinson's disease by examining olfactory neurons of patients. METHODS: Thirty-eight patients (26 de novo, newly diagnosed) and 31 sex/age-matched healthy controls underwent noninvasive mucosa brushing for olfactory neurons collection, and standard clinical assessment. Gene expression levels of prokineticin-2, prokineticin-2 receptors type 1 and 2, and prokineticin-2-long peptide were measured in olfactory neurons by real-time polymerase chain reaction (PCR); moreover, the prokineticin-2 protein and α-synuclein species (total and oligomeric) were quantified by immunofluorescence staining. RESULTS: Prokineticin-2 expression was significantly increased in Parkinson's disease. De novo patients had higher prokineticin-2 levels, directly correlated with Movement Disorder Society-Sponsored Revision of the Unified Parkinson Disease Rating Scale (MDS-UPDRS) part III motor score. In addition, oligomeric α-synuclein was higher in Parkinson's disease and directly correlated with prokineticin-2 protein levels. Total α-synuclein did not differ between patients and controls. INTERPRETATION: Prokineticin-2 is a chemokine showing neuroprotective effects in experimental models of Parkinson's disease, but translational proof of its role in patients is still lacking. Here, we used olfactory neurons as the ideal tissue to analyze molecular stages of neurodegeneration in vivo, providing unprecedented evidence that the prokineticin-2 pathway is activated in patients with Parkinson's disease. Specifically, prokineticin-2 expression in olfactory neurons was higher at early disease stages, proportional to motor severity, and associated with oligomeric α-synuclein accumulation. These data, consistently with preclinical findings, support prokineticin-2 as a candidate target in Parkinson's disease, and validate reliability of olfactory neurons to reflect pathological changes of the disease. ANN NEUROL 2023;93:196-204.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Schirinzi T, Maftei D, Passali FM, et al. Olfactory Neuron Prokineticin-2 as a Potential Target in Parkinson's Disease. Ann Neurol. 2022. PMID: 36218142. doi:10.1002/ana.26526

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。